JP2009535429A - Ｃｇｒｐ受容体アンタゴニストとしての束縛された化合物 - Google Patents
Ｃｇｒｐ受容体アンタゴニストとしての束縛された化合物 Download PDFInfo
- Publication number
- JP2009535429A JP2009535429A JP2009510047A JP2009510047A JP2009535429A JP 2009535429 A JP2009535429 A JP 2009535429A JP 2009510047 A JP2009510047 A JP 2009510047A JP 2009510047 A JP2009510047 A JP 2009510047A JP 2009535429 A JP2009535429 A JP 2009535429A
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- mmol
- mixture
- chloro
- indazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CN1CC*(*)CC1 Chemical compound CN1CC*(*)CC1 0.000 description 10
- BRQJTDURZKRGHM-UHFFFAOYSA-N C=Cc1cccnc1[N+]([O-])=O Chemical compound C=Cc1cccnc1[N+]([O-])=O BRQJTDURZKRGHM-UHFFFAOYSA-N 0.000 description 1
- UVBVUCARTKSNMW-UHFFFAOYSA-N CC(C)(C)CN(Cc(c1c2[nH]nc1)c(CC1CC(OC)=O)cc2Br)C1=O Chemical compound CC(C)(C)CN(Cc(c1c2[nH]nc1)c(CC1CC(OC)=O)cc2Br)C1=O UVBVUCARTKSNMW-UHFFFAOYSA-N 0.000 description 1
- KBHGSXARBLPLBO-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC1N(Cc1c(C(C2)C22NC(OCc3ccccc3)=O)ccc3c1cn[nH]3)C2=O)=O Chemical compound CC(C)(C)OC(N(CC1)CC1N(Cc1c(C(C2)C22NC(OCc3ccccc3)=O)ccc3c1cn[nH]3)C2=O)=O KBHGSXARBLPLBO-UHFFFAOYSA-N 0.000 description 1
- JTOYMRROBPBLNQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1NCCc(nccc1)c1[N+]([O-])=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1NCCc(nccc1)c1[N+]([O-])=O)=O JTOYMRROBPBLNQ-UHFFFAOYSA-N 0.000 description 1
- MRWRSTHVSJHZGK-HMAPJEAMSA-N CC(C)(C)OC(N/C(/C(OC)=O)=C\c(cc1)c(COC(C)=O)cc1OCc1ccccc1)=O Chemical compound CC(C)(C)OC(N/C(/C(OC)=O)=C\c(cc1)c(COC(C)=O)cc1OCc1ccccc1)=O MRWRSTHVSJHZGK-HMAPJEAMSA-N 0.000 description 1
- QYDQCBVDBHELCK-UHFFFAOYSA-N CC(C)(C)OC(Nc(c(C)c1)cc(COC(C)=O)c1I)=O Chemical compound CC(C)(C)OC(Nc(c(C)c1)cc(COC(C)=O)c1I)=O QYDQCBVDBHELCK-UHFFFAOYSA-N 0.000 description 1
- KGBRESBAPMQXDH-HMAPJEAMSA-N CC(C)(C)OC(Nc1c(C)c(COC(C)=O)c(/C=C(/C(OC)=O)\OC(c2ccccc2)=O)cc1)=O Chemical compound CC(C)(C)OC(Nc1c(C)c(COC(C)=O)c(/C=C(/C(OC)=O)\OC(c2ccccc2)=O)cc1)=O KGBRESBAPMQXDH-HMAPJEAMSA-N 0.000 description 1
- SJSJKHNBAZEEDK-UHFFFAOYSA-N CC(Nc(c(C)c1COC(C)=O)c(C)cc1I)=O Chemical compound CC(Nc(c(C)c1COC(C)=O)c(C)cc1I)=O SJSJKHNBAZEEDK-UHFFFAOYSA-N 0.000 description 1
- ZDBPLOJGFZJKTJ-HNNXBMFYSA-N CCOC(C[C@H](Cc(cc1)c(COC(C)=O)c(C)c1N)C(OCC)=O)=O Chemical compound CCOC(C[C@H](Cc(cc1)c(COC(C)=O)c(C)c1N)C(OCC)=O)=O ZDBPLOJGFZJKTJ-HNNXBMFYSA-N 0.000 description 1
- JRSUORJZCOQXHB-LBPRGKRZSA-N CCOC(C[C@H](Cc(cc1Br)c(COC(C)=O)c2c1[nH]nc2Br)C(OCC)=O)=O Chemical compound CCOC(C[C@H](Cc(cc1Br)c(COC(C)=O)c2c1[nH]nc2Br)C(OCC)=O)=O JRSUORJZCOQXHB-LBPRGKRZSA-N 0.000 description 1
- MLKRFTZGLJNYTR-VIFPVBQESA-N COC(C[C@H](CCc(cc1Br)c(CO)c2c1[nH]nc2Cl)C(OC)=O)=O Chemical compound COC(C[C@H](CCc(cc1Br)c(CO)c2c1[nH]nc2Cl)C(OC)=O)=O MLKRFTZGLJNYTR-VIFPVBQESA-N 0.000 description 1
- PTJCEACDZMDJFW-VIFPVBQESA-N COC(C[C@H](Cc(cc1Cl)c(CCl)c2c1[nH]nc2)C(OC)=O)=O Chemical compound COC(C[C@H](Cc(cc1Cl)c(CCl)c2c1[nH]nc2)C(OC)=O)=O PTJCEACDZMDJFW-VIFPVBQESA-N 0.000 description 1
- BXTYCDUFLOSIGX-JTQLQIEISA-N COC[n]1ncc2c1c(Cl)cc(C[C@H]1CC(O)=O)c2CN(CC(F)(F)F)C1=O Chemical compound COC[n]1ncc2c1c(Cl)cc(C[C@H]1CC(O)=O)c2CN(CC(F)(F)F)C1=O BXTYCDUFLOSIGX-JTQLQIEISA-N 0.000 description 1
- ZDYIZSQVHRUVMR-ZKMFCFPVSA-N CS(OC(CNCC1)C1N(Cc1c(CC[C@H]2NC(OCc3ccccc3)=O)ccc3c1cn[nH]3)C2=O)(=O)=O Chemical compound CS(OC(CNCC1)C1N(Cc1c(CC[C@H]2NC(OCc3ccccc3)=O)ccc3c1cn[nH]3)C2=O)(=O)=O ZDYIZSQVHRUVMR-ZKMFCFPVSA-N 0.000 description 1
- OBDBVSGXUVGBBY-FQEVSTJZSA-N C[n]1ncc2c(CN(CC(F)(F)F)C([C@H](CC(N(CC3)CCC3N(CCc(cccc3)c3N3)C3=O)=O)C3)=O)c3cc(Cl)c12 Chemical compound C[n]1ncc2c(CN(CC(F)(F)F)C([C@H](CC(N(CC3)CCC3N(CCc(cccc3)c3N3)C3=O)=O)C3)=O)c3cc(Cl)c12 OBDBVSGXUVGBBY-FQEVSTJZSA-N 0.000 description 1
- NFMICTOBQBVEOG-UHFFFAOYSA-N O=C(C(C1CCNCC1)=C1)Nc2c1[s]c(Cl)c2 Chemical compound O=C(C(C1CCNCC1)=C1)Nc2c1[s]c(Cl)c2 NFMICTOBQBVEOG-UHFFFAOYSA-N 0.000 description 1
- CWWPGYUYJZYURK-UHFFFAOYSA-N O=C(C(C1CCNCC1)=C1)Nc2c1[s]cc2Cl Chemical compound O=C(C(C1CCNCC1)=C1)Nc2c1[s]cc2Cl CWWPGYUYJZYURK-UHFFFAOYSA-N 0.000 description 1
- GTNRGOREAZJNLJ-SFHVURJKSA-N O=C(C[C@H](CCc(cc1Cl)c(CN2CC(F)(F)F)c3c1[nH]nc3)C2=O)N(CC1)CCC1N(CCc(nccc1)c1N1)C1=O Chemical compound O=C(C[C@H](CCc(cc1Cl)c(CN2CC(F)(F)F)c3c1[nH]nc3)C2=O)N(CC1)CCC1N(CCc(nccc1)c1N1)C1=O GTNRGOREAZJNLJ-SFHVURJKSA-N 0.000 description 1
- FWTAKRSSDLWRKM-XMMPIXPASA-N O=C(N[C@H](Cc(cc1)c(CN2Cc3ccc(C(F)(F)F)cc3)c3c1[nH]nc3)C2=O)OCc1ccccc1 Chemical compound O=C(N[C@H](Cc(cc1)c(CN2Cc3ccc(C(F)(F)F)cc3)c3c1[nH]nc3)C2=O)OCc1ccccc1 FWTAKRSSDLWRKM-XMMPIXPASA-N 0.000 description 1
- MXJNFSQCMIGUDB-UHFFFAOYSA-N O=C(Nc1c(CC2)cccc1)N2C1CCN(Cc2ccccc2)CC1 Chemical compound O=C(Nc1c(CC2)cccc1)N2C1CCN(Cc2ccccc2)CC1 MXJNFSQCMIGUDB-UHFFFAOYSA-N 0.000 description 1
- ROGQUNNTHOOXBR-UHFFFAOYSA-N OC(CC(Cc(cc1Br)c(CN2CC3CC3)c3c1[nH]nc3)C2=O)=O Chemical compound OC(CC(Cc(cc1Br)c(CN2CC3CC3)c3c1[nH]nc3)C2=O)=O ROGQUNNTHOOXBR-UHFFFAOYSA-N 0.000 description 1
- SELFLFPDMWJPQL-ZETCQYMHSA-N OC(C[C@H](Cc(cc1Br)c(CN2CC(F)(F)F)c3c1[nH]nc3Cl)C2=O)=O Chemical compound OC(C[C@H](Cc(cc1Br)c(CN2CC(F)(F)F)c3c1[nH]nc3Cl)C2=O)=O SELFLFPDMWJPQL-ZETCQYMHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79740006P | 2006-05-03 | 2006-05-03 | |
| US11/742,626 US7470680B2 (en) | 2006-05-03 | 2007-05-01 | Constrained compounds as CGRP-receptor antagonists |
| PCT/US2007/067998 WO2007131020A2 (en) | 2006-05-03 | 2007-05-02 | Constrained compounds as cgrp-receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535429A true JP2009535429A (ja) | 2009-10-01 |
| JP2009535429A5 JP2009535429A5 (https=) | 2010-06-17 |
Family
ID=38544174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510047A Pending JP2009535429A (ja) | 2006-05-03 | 2007-05-02 | Ｃｇｒｐ受容体アンタゴニストとしての束縛された化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7470680B2 (https=) |
| EP (1) | EP2013214B1 (https=) |
| JP (1) | JP2009535429A (https=) |
| KR (1) | KR20090018930A (https=) |
| AR (1) | AR060845A1 (https=) |
| AU (1) | AU2007248038A1 (https=) |
| BR (1) | BRPI0709759A2 (https=) |
| CA (1) | CA2651033A1 (https=) |
| IL (1) | IL195027A0 (https=) |
| MX (1) | MX2008013760A (https=) |
| NO (1) | NO20084564L (https=) |
| PE (1) | PE20080232A1 (https=) |
| TW (1) | TW200813063A (https=) |
| WO (1) | WO2007131020A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| EP2120564A4 (en) * | 2006-12-20 | 2011-05-04 | Merck Sharp & Dohme | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS |
| JP2011512410A (ja) * | 2008-02-19 | 2011-04-21 | メルク・シャープ・エンド・ドーム・コーポレイション | イミダゾベンゾアゼピンｃｇｒｐ受容体アンタゴニスト |
| US8685969B2 (en) | 2010-06-16 | 2014-04-01 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| WO2024220626A1 (en) * | 2023-04-20 | 2024-10-24 | Azkarra Therapeutics, Inc. | Small molecule modulators of ogg1 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082602A2 (en) * | 2003-03-14 | 2004-09-30 | Merck & Co. Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
| WO2004092166A2 (en) * | 2003-04-15 | 2004-10-28 | Merck & Co., Inc. | Cgrp receptor antagonists |
| WO2005000807A2 (en) * | 2003-06-26 | 2005-01-06 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| WO2006031606A2 (en) * | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Carboxamide spirolactam cgrp receptor antagonists |
| WO2006041830A2 (en) * | 2004-10-07 | 2006-04-20 | Merck & Co., Inc. | Cgrp receptor antagonists |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205293B2 (en) | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| JP4705908B2 (ja) * | 2003-04-15 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｇｒｐ受容体拮抗薬 |
| CA2529196A1 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| JP4705922B2 (ja) | 2004-01-29 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｇｒｐ受容体拮抗薬 |
| BRPI0517418A (pt) | 2004-10-13 | 2008-10-07 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça |
| AU2005295855B2 (en) | 2004-10-14 | 2011-08-18 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| AU2005299852B2 (en) | 2004-10-22 | 2011-08-04 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| CA2594940A1 (en) | 2005-01-18 | 2006-07-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
| CN101208303A (zh) | 2005-03-14 | 2008-06-25 | 默克公司 | Cgrp受体拮抗剂 |
| WO2007016087A2 (en) | 2005-07-29 | 2007-02-08 | Merck & Co., Inc. | Heterocyclic benzodiazepine cgrp receptor antagonists |
| EP2120564A4 (en) | 2006-12-20 | 2011-05-04 | Merck Sharp & Dohme | BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS |
-
2007
- 2007-05-01 US US11/742,626 patent/US7470680B2/en active Active
- 2007-05-02 EP EP07761726.4A patent/EP2013214B1/en active Active
- 2007-05-02 KR KR1020087029499A patent/KR20090018930A/ko not_active Withdrawn
- 2007-05-02 MX MX2008013760A patent/MX2008013760A/es not_active Application Discontinuation
- 2007-05-02 JP JP2009510047A patent/JP2009535429A/ja active Pending
- 2007-05-02 AR ARP070101906A patent/AR060845A1/es not_active Application Discontinuation
- 2007-05-02 WO PCT/US2007/067998 patent/WO2007131020A2/en not_active Ceased
- 2007-05-02 AU AU2007248038A patent/AU2007248038A1/en not_active Abandoned
- 2007-05-02 PE PE2007000536A patent/PE20080232A1/es not_active Application Discontinuation
- 2007-05-02 CA CA002651033A patent/CA2651033A1/en not_active Abandoned
- 2007-05-02 BR BRPI0709759-0A patent/BRPI0709759A2/pt not_active IP Right Cessation
- 2007-05-03 TW TW096115732A patent/TW200813063A/zh unknown
-
2008
- 2008-10-30 IL IL195027A patent/IL195027A0/en unknown
- 2008-10-30 NO NO20084564A patent/NO20084564L/no not_active Application Discontinuation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082602A2 (en) * | 2003-03-14 | 2004-09-30 | Merck & Co. Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
| WO2004092166A2 (en) * | 2003-04-15 | 2004-10-28 | Merck & Co., Inc. | Cgrp receptor antagonists |
| WO2004092168A1 (en) * | 2003-04-15 | 2004-10-28 | Merck & Co., Inc. | Cgrp receptor antagonists |
| WO2005000807A2 (en) * | 2003-06-26 | 2005-01-06 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| WO2006031606A2 (en) * | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Carboxamide spirolactam cgrp receptor antagonists |
| WO2006041830A2 (en) * | 2004-10-07 | 2006-04-20 | Merck & Co., Inc. | Cgrp receptor antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090018930A (ko) | 2009-02-24 |
| WO2007131020A2 (en) | 2007-11-15 |
| US7470680B2 (en) | 2008-12-30 |
| CA2651033A1 (en) | 2007-11-15 |
| EP2013214A2 (en) | 2009-01-14 |
| AR060845A1 (es) | 2008-07-16 |
| TW200813063A (en) | 2008-03-16 |
| MX2008013760A (es) | 2008-11-14 |
| AU2007248038A1 (en) | 2007-11-15 |
| WO2007131020A3 (en) | 2008-01-17 |
| BRPI0709759A2 (pt) | 2011-10-25 |
| US20070259851A1 (en) | 2007-11-08 |
| PE20080232A1 (es) | 2008-04-11 |
| IL195027A0 (en) | 2009-08-03 |
| NO20084564L (no) | 2008-12-02 |
| EP2013214B1 (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7544680B2 (en) | Constrained compounds as CGRP-receptor antagonists | |
| JP5116687B2 (ja) | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 | |
| JP6258537B2 (ja) | Ｃｇｒｐ受容体アンタゴニスト | |
| WO2007130860A2 (en) | Constrained compounds as cgrp-receptor antagonists | |
| US7470680B2 (en) | Constrained compounds as CGRP-receptor antagonists | |
| CN112584898A (zh) | P2x3受体拮抗剂 | |
| ES2368456T3 (es) | Compuestos restringidos como antagonistas del receptor de cgrp. | |
| CN101495480B (zh) | 作为降钙素基因相关肽受体拮抗剂的受限化合物 | |
| US20090054440A1 (en) | Quinoline derivatives as neurokinin receptor antagonists | |
| AU2019363657A1 (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
| CN101094854A (zh) | 作为cgrp受体拮抗剂的受限化合物 | |
| HK1171742A (en) | Tricyclic pyrazol amine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100423 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100423 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121016 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121016 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130312 |